Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FGFR2 Fusion”

31 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 31 results

Testing effectiveness (Phase 2)Looking for participantsNCT05678270
What this trial is testing

ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic Cholangiocarcinoma (ICC)
Beijing InnoCare Pharma Tech Co., Ltd. 70
Not applicableUnknownNCT04921553
What this trial is testing

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

Who this might be right for
CancerCancer MetastaticNTRK Gene Fusion Overexpression+13 more
Centre Leon Berard 500
Testing effectiveness (Phase 2)Looking for participantsNCT06728410
What this trial is testing

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Who this might be right for
Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
Mehmet Akce 38
Testing effectiveness (Phase 2)Study completedNCT03230318
What this trial is testing

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic CholangiocarcinomaCombined Hepatocellular and Cholangiocarcinoma
Basilea Pharmaceutica 148
Not applicableNot Yet RecruitingNCT07142226
What this trial is testing

Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC

Who this might be right for
Biliary Tract Cancer
CHA University 200
Large-scale testing (Phase 3)Looking for participantsNCT04353375
What this trial is testing

HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

Who this might be right for
Advanced Intrahepatic CholangiocarcinomaSolid Tumor, Adult
Hutchmed 235
Testing effectiveness (Phase 2)Looking for participantsNCT06439485
What this trial is testing

Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Who this might be right for
Advanced CholangiocarcinomaFGFR2 Fusion
M.D. Anderson Cancer Center 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07359820
What this trial is testing

Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

Who this might be right for
FGFR2 Gene Fusion/RearrangementOther Solid Tumors, Adult
Elevar Therapeutics 30
Large-scale testing (Phase 3)Ended earlyNCT03773302
What this trial is testing

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Who this might be right for
Advanced CholangiocarcinomaFGFR2 Gene Mutation
QED Therapeutics, a BridgeBio company 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT05174650
What this trial is testing

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Who this might be right for
Intrahepatic Cholangiocarcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 27
Testing effectiveness (Phase 2)Ended earlyNCT02150967
What this trial is testing

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

Who this might be right for
Advanced CholangiocarcinomaFGFR2 Gene Mutation
QED Therapeutics, a BridgeBio company 143
Large-scale testing (Phase 3)Ended earlyNCT04093362
What this trial is testing

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Who this might be right for
Advanced CholangiocarcinomaFGFR2 Gene Rearrangements
Taiho Oncology, Inc. 10
Testing effectiveness (Phase 2)Looking for participantsNCT06906562
What this trial is testing

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

Who this might be right for
Advanced Pancreatic CarcinomaMetastatic Pancreatic CarcinomaStage II Pancreatic Cancer AJCC v8+2 more
Sameek Roychowdhury 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT04238715
What this trial is testing

E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

Who this might be right for
Cholangiocarcinoma
Eisai Co., Ltd. 63
Early research (Phase 1)Looking for participantsNCT06160752
What this trial is testing

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

Who this might be right for
Locally Advanced CholangiocarcinomaIntrahepatic CholangiocarcinomaSolid Tumor+1 more
Tyra Biosciences, Inc 40
Not applicableStudy completedNCT02450123
What this trial is testing

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Who this might be right for
Refractory Solid Tumors
Samsung Medical Center 1
Early research (Phase 1)Study completedNCT01004224
What this trial is testing

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Who this might be right for
Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3Squamous Lung Cancer With FGFR1 AmplificationBladder Cancer With FGFR3 Mutation or Fusion+3 more
Novartis Pharmaceuticals 208
Testing effectiveness (Phase 2)WithdrawnNCT05222165
What this trial is testing

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

Who this might be right for
Advanced Solid TumorCNS TumorRecurrent WHO Grade II Glioma
Helsinn Healthcare SA
Testing effectiveness (Phase 2)Active Not RecruitingNCT04526106
What this trial is testing

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Who this might be right for
FGFR2 AmplificationFGFR2 Gene MutationFGFR2 Gene Fusion/Rearrangement+5 more
Elevar Therapeutics 490
Not applicableLooking for participantsNCT06793709
What this trial is testing

A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

Who this might be right for
Biliary Tract Cancer
Eisai Co., Ltd. 60
Load More Results